Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Muse Effective For Many Impotent Men Who Fail Or Discontinue Injection Therapy MOUNTAIN VIEW, CA -- July 16, 1998 -- A study published in the journal Urology shows that Vivus, Inc.’s Muse(R) (alprostadil) is an effective treatment for erectile dysfunction in many men who have failed or discontinued intracavernous injection therapy. The study found that in patients who failed or discontinued prior injection therapy, 58 percent achieved an erection sufficient for intercourse on at least one of the four doses of Muse (125 mcg, 250 mcg, 500 mcg, and 1,000 mcg) in clinic. Forty-seven percent of these successful patients also reported intercourse during the home treatment phase of the study. As with other studies, most patients required the higher doses of Muse. The study evaluated the safety and efficacy of Muse in 452 patients diagnosed with chronic, organic erectile dysfunction who had a prior history of intracavernous injection therapy. A patient questionnaire revealed that 47 percent rated injection therapy as not effective or sometimes effective; the remaining patients rated injection therapy as effective. All patients had discontinued intracavernous treatment at least 30 days prior to this study and had been unable to achieve an erection sufficient for sexual intercourse without intracavernous injection therapy or other treatment for at least three months. "In the past, men who failed injection therapy were often offered penile implant surgery as their only option. This study demonstrated that Muse can be an effective option in men who fail to have an adequate response to injection therapy," said senior study author Kevin McVary, M.D., associate professor of urology at Northwestern University School of Medicine. "There are many algorithms for treating erectile dysfunction. These results show that success or failure with one treatment, intracavernosal injections, does not foretell response to another treatment, Muse. My hope is that these results will open up treatment options for patients who are not adequately treated." More information on: Muse, Vivus, Inc. E-mail this page to a friend or colleague! To print, use this version